Conclusion of Joint Sales Agreement on the Overactive Bladder Therapeutic Drug HOB-294 (oxybutynin hydrochloride transdermal therapeutic formulation)
Hisamitsu Pharmaceutical Co., Inc., (Head Office: Tosu City, Saga Prefecture, Japan; President & CEO: Hirotaka Nakatomi; hereinafter referred to as Hisamitsu) and Asahi Kasei Pharma Corp. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Toshio Asano) hereby announce that as of December 10, 2012, they have concluded a Joint Sales Agreement in Japan for HOB-294 (oxybutynin hydrochloride transdermal therapeutic formulation), which is being developed by Hisamitsu as an overactive bladder therapeutic drug.
Under the terms of this agreement, Hisamitsu will obtain manufacturing and sales approval for the product, and the two companies will subsequently carry out joint sales activities. After the product is launched on the market, each company will carry out independent product distribution and information provision/gathering activities under a one-brand, two-channel setup.
HOB-294 is a transdermal therapeutic formulation developed as a tape formulation which contains oxybutynin hydrochloride, a highly therapeutically-effective agent for the treatment of overactive bladder showing symptoms of urinary urgency, frequent urination, etc., by using Hisamitsuís TDDS (Transdermal Drug Delivery System) technology. Hisamitsu has been developing this product in the expectation that its drug efficacy will last through the stable maintenance of drug levels in the blood.
A new drug application for this product was submitted in May 2012 and Hisamitsu will make further endeavors to obtain approval by the end of FY 2013.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.